Inve US ▾
WVWVE

Wave Life Sciences (WVE) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Jul 30, 2026

Source: earnings call transcript

Executive summary

Wave Life Sciences Q2 FY26 — Obesity and AATD Programs Advance, Regulatory Pathway for 006 Explored

Wave Life Sciences advanced its lead RNAi and RNA editing programs, WVE-007 for obesity and WVE-006 for AATD, into their next development stages, leveraging proprietary chemistry and human genetic insights. The company is actively pursuing an accelerated approval pathway for WVE-006 and initiating combination and maintenance studies for WVE-007, while maintaining a strong cash position. The strategy includes exploring partnerships for DMD programs amidst a changing landscape.

Highlights

5

  • WVE-007 for obesity showed robust and durable silencing, supporting once or twice yearly dosing, with substantial reductions in visceral and subcutaneous fat without muscle loss.

  • WVE-006 for AATD demonstrated a compelling therapeutic profile, restoring dynamic AAT protein response and addressing both lung and liver manifestations.

  • FDA granted a meeting request to discuss an accelerated approval pathway for WVE-006, expected at the end of summer.

  • Ended the quarter with $490.6 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into Q3 2028.

  • WVE-007 Phase IIa dosing is underway in individuals with higher BMI and comorbidities, with strong enrollment interest.

Concerns

5

  • Revenue for Q2 FY26 was $2.3 million, down from $8.7 million in Q2 FY25.

  • R&D expenses increased to $51.3 million in Q2 FY26 from $43.5 million in Q2 FY25 due to clinical program advancement.

  • G&A expenses increased to $24.8 million in Q2 FY26 from $18 million in Q2 FY25 to support expanding pipeline.

  • Net loss widened to $69.4 million in Q2 FY26 from $50.5 million in Q2 FY25.

  • DMD programs (N531, 003) are exploring partnership opportunities due to evolving regulatory and commercial landscape, with potential NDA filing contingent on partnership.

Guidance & targets

CategoryTargetConfidence
WVE-007 combination and maintenance studies initiation
Initiate clinical studies
medium materiality
High
WVE-008 CTA submission
CTA submission
medium materiality
High
Cash runway
Into Q3 2028
high materiality
High
Annual Investor Day
Host event
low materiality
High
WVE-007 Phase I 600mg cohort data
Share additional data
medium materiality
High
WVE-006 600mg monthly dosing cohort data
Share data
medium materiality
High
WVE-006 FDA meeting for accelerated approval
Meeting with FDA
high materiality
High

Deals & partnerships

GSK Ongoing collaboration agreement

Revenue for Q2 FY26 was $2.3 million compared to $8.7 million in Q2 FY25.

Not stated (potential partners) Seek partnership opportunities for HD and DMD programs

Given evolving regulatory and commercial landscape in DMD, exploring potential partnerships in advance of filing an NDA for N531.

Risks & headwinds

High discontinuation rates for GLP-1 therapies Within the first year of treatment

Up to 70% of patients discontinue within the first year.

Mitigation:WVE-007 maintenance therapy could address tolerability, treatment burden, or anhedonia issues.

Evolving regulatory and commercial landscape in DMD Ongoing

Not quantified.

Mitigation:Exploring potential partnerships for N531 and 003 in advance of filing an NDA for N531. Evaluating the pathway for existing PMO 53 Golodirsen's potential full approval.

Silencing approaches for PNPLA3 liver disease may exacerbate the disease

Dose-dependent increases in liver enzymes observed in clinical trials of PNPLA3 silencing.

Mitigation:WVE-008 uses an RNA editing approach to restore functional protein, which is expected to reverse steatosis and fibrosis, rather than silencing.

What to watch in Q3 FY26

WVE-006 accelerated approval pathway discussion with FDA

End of summer (2026)
Current FDA granted meeting request
Target Feedback from FDA on potential accelerated approval pathway and registrational study design

Why it matters

This will inform the development timeline and potential market entry for WVE-006, a key RNA editing program for AATD.

We're excited to announce today that the FDA granted our request for a meeting, which is planned for the end of this summer. During this, we intend to discuss a potential accelerated approval pathway for 006 in AATD.

Find out whether WVE delivers this. Inve re-checks your case every morning.

Q&A highlights

Confirm if Phase IIa aims for 5% weight loss for obesity indication and how 007 combination therapy differentiates from others.

Paul Bolno confirmed the Phase IIa is designed to elicit the regulatory threshold of 5% weight loss, but also to unlock broader cardiometabolic indications (MASH, T2D) by evaluating biomarkers like MRI-PDFF, HbA1c, and lipids. For combination therapy, he expects 007 to show better data due to greater potency and durability, and highlighted maintenance as a unique differentiation opportunity.

“the Phase IIa is designed, as you point out, to be able to elicit that regulatory and cross that regulatory threshold of 5%.”

asked by Yun Zhong · answered by Paul Bolno

2 min read 6 chapters

Detailed narrative

Proprietary Chemistry and Platform Advancements

Wave Life Sciences emphasizes its proprietary chemistry and SpiNA sRNA design as key differentiators, enhancing potency and durability compared to industry-leading sRNA designs. This platform enables rapid advancement from novel genetic targets to clinical proof of mechanism, as demonstrated by recent positive data sets. The company plans to host an Annual Investor Day in the fall to highlight further platform advancements and work on its bifunctional modality.

WVE-007 for Obesity and Cardiometabolic Diseases

WVE-007, an INHBE GalNAc-siRNA, aims to address obesity by selectively reducing excess fat (visceral and subcutaneous) while preserving skeletal muscle, a differentiated approach from incretin therapies. The Phase IIa INLIGHT trial is enrolling individuals with higher BMIs (35-50) and comorbidities, with and without type 2 diabetes, across two dose levels (240mg and 400mg) in four cohorts of 40 patients each. This design allows for evaluation of body composition, weight loss, and potential in MASH, type 2 diabetes, and other cardiometabolic diseases.

WVE-007 Combination and Maintenance Strategies

Preclinical data supports combination with incretins, showing approximately twofold greater weight loss, and post-incretin maintenance, demonstrating the ability to curtail weight regain. These strategies aim to address high GLP-1 discontinuation rates (up to 70% within the first year) due to tolerability, treatment burden, or anhedonia, offering a new commercial frontier for sustained health benefits. Clinical studies for both combination and maintenance are planned to initiate this year.

WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD)

WVE-006 is an RNA editing candidate designed to treat both lung and liver manifestations of AATD by restoring dynamic AAT protein response. The goal is to recapitulate an MZ-like phenotype, reducing Z-AAT and providing protective basal M-AAT levels with a preserved acute phase response. The FDA has granted a meeting request for the end of summer to discuss a potential accelerated approval pathway for 006, which could inform registrational plans for the 200,000 individuals in the U.S. and Europe living with homozygous ZZ AATD.

WVE-008 for PNPLA3 Liver Disease

WVE-008 is the second RNA editing candidate, targeting homozygous PNPLA3 I148M liver disease, affecting 9 million individuals in the U.S. and Europe who have a ninefold higher risk of dying from liver disease. The RNA editing approach aims to correct the I148M variant to restore functional PNPLA3 activity and lipid mobilization, reversing steatosis and fibrosis, contrasting with silencing approaches that may exacerbate the disease. A CTA submission is on track for 2026, with plans to leverage genotyped populations for efficient enrollment.

DMD Program Strategy

Wave Life Sciences is exploring potential partnerships for its Duchenne Muscular Dystrophy (DMD) programs, N531 and 003, in advance of filing an NDA for N531. This decision is influenced by the evolving regulatory and commercial landscape in DMD, including the potential full approval of existing therapies, and aims to ensure prudent investment of funds.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.